(Q43288456)

18 November 2017

title

Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension (English)

1 reference

18 November 2017

Toshihiko Ishimitsu

1

1 reference

18 November 2017

Atsushi Numabe

2

1 reference

18 November 2017

Toshihide Masuda

3

1 reference

18 November 2017

Tomoyuki Akabane

4

1 reference

18 November 2017

Atsushi Okamura

5

1 reference

18 November 2017

Junichi Minami

6

1 reference

18 November 2017

Hiroaki Matsuoka

7

1 reference

18 November 2017

publication date

21 August 2009

1 reference

18 November 2017

published in

Hypertension Research

1 reference

18 November 2017

volume

32

1 reference

18 November 2017

issue

11

1 reference

18 November 2017

page(s)

962-968

1 reference

https://scigraph.springernature.com/pub.10.1038/hr.2009.133

18 November 2017

exact match

0 references

cites work

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Is fixed combination therapy appropriate for initial hypertension treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Revised equations for estimated GFR from serum creatinine in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Cardio-ankle vascular index is superior to brachial-ankle pulse wave velocity as an index of arterial stiffness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Arterial stiffness and cardiovascular outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Arterial stiffness: pathophysiology and clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Reproducibility of arterial stiffness indices (pulse wave velocity and augmentation index) simultaneously assessed by automated pulse wave analysis and their associated risk factors in essential hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Clinical usefulness and limitations of brachial-ankle pulse wave velocity in the evaluation of cardiovascular complications in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Effect of antihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Review of aldosterone- and angiotensin II-induced target organ damage and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Renin-angiotensin system and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Aldosterone in chronic kidney and cardiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

C-reactive protein in hypertension: clinical significance and predictive value

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

C-reactive protein gene polymorphisms, C-reactive protein blood levels, and cardiovascular disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Role of oxidized low density lipoprotein in atherogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Oxidized LDL and HDL: antagonists in atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

C-reactive protein (CRP)-lowering agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Clinical studies of CS-866, the newest angiotensin II receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Hypertension in four African-origin populations: current 'Rule of Halves', quality of blood pressure control and attributable risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Heart rate as a predictor of mortality: the MATISS project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

Current status of antihypertensive prescription and associated blood pressure control in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

7 January 2021

Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004)

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

7 January 2021

Aldosterone and end-organ damage

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

7 January 2021

Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

7 January 2021

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

7 January 2021

Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist.

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

7 January 2021

Influence of heart rate on mortality among persons with hypertension: the Framingham Study

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

7 January 2021

Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.133

7 January 2021

Identifiers

DOI

10.1038/HR.2009.133

1 reference

18 November 2017

1 reference